SPRO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SPRO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Spero Therapeutics's purchase of property, plant, equipment for the three months ended in Sep. 2024 was $0.00 Mil. It means Spero Therapeutics spent $0.00 Mil on purchasing property, plant, equipment. Spero Therapeutics's purchase of property, plant, equipment for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00Mil.
Compared with last quarter ($0.00 Mil in Jun. 2024 ), Spero Therapeutics spent the same money on purchasing property, plant, equipment in Sep. 2024 ($0.00 Mil).
The historical data trend for Spero Therapeutics's Purchase Of Property, Plant, Equipment can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spero Therapeutics Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Purchase Of Property, Plant, Equipment | Get a 7-Day Free Trial | -0.31 | -0.16 | - | - | - |
Spero Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Purchase Of Property, Plant, Equipment | Get a 7-Day Free Trial | - | - | - | - | - |
The amount used to purchase PPE.
Purchase Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Spero Therapeutics's Purchase Of Property, Plant, Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.
Timothy Keutzer | officer: Chief Development Officer | C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139 |
Ankit Mahadevia | director, officer: See Remarks | C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVE., 14TH FLOOR, CAMBRIDGE MA 02139 |
Sath Shukla | officer: Chief Financial Officer | C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BUILDING #34, BOSTON MA 02129 |
Kamal Hamed | officer: Chief Medical Officer | 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139 |
Tamara L Joseph | officer: Chief Legal Officer | 32 GARRISON STREET, APT 50-103, BOSTON MA 02116 |
Aquilo Capital Management, Llc | 10 percent owner | ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO CA 94129 |
Kathleen Tregoning | director | C/O CEREVEL THERAPEUTICS HOLDINGS, INC., 131 DARTMOUTH STREET SUITE 502, BOSTON MA 02116 |
Cristina Larkin | officer: Chief Operating Officer | C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139 |
Aquilo Capital, L.p. | 10 percent owner | ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, THE PRESIDIO, SAN FRANCISCO CA 94129 |
Scott Thomas Jackson | director | 303B COLLEGE ROAD EAST, PRINCETON NJ 08540 |
Stephen J. Dipalma | officer: Interim CFO | C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139 |
Cynthia Smith | director | 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
Pottage John C Jr | director | ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511 |
Plc Glaxosmithkline | 10 percent owner | 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS |
Joel Sendek | officer: Chief Financial Officer | C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139 |
From GuruFocus
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 08-06-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By Marketwired • 06-03-2024
By Marketwired • 05-08-2024
By Marketwired • 05-16-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By Marketwired • 11-14-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.